FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120133688> ?p ?o ?g. }

• W3120133688 abstract "Abstract Background Necrotizing enterocolitis (NEC) remains a fatal gastrointestinal disorder in neonates and has very limited therapeutic options. Sialylated human milk oligosaccharides (SHMOs) improve pathological changes in experimental NEC models. The objectives of this study were to investigate the involvement of NLRP3 inflammasome in NEC pathology and to explore the effects of SHMOs on toll-like receptor 4 (TLR4)/nuclear factor κB (NF-κB)/NLRP3 inflammatory pathway in experimental NEC. Methods The intestinal-tissue segments were collected from NEC infants, NLRP3 and caspase-1 positive cell were examined by immunohistochemistry. Newborn rats were hand-fed with formula containing or non-containing SHMOs (1500 mg/L) and exposed to hypoxia/cold stress to induce experimental NEC. The NEC pathological scores were evaluated; ileum protein expression of membrane TLR4 (mTLR4), inhibitor κB-α (IκB-α), NF-κB p65 subunit and phospho-NF-κB p65, as well as NLRP3 and caspase-1 were analyzed; ileum concentrations of interleukin-1β, interleukin-6, tumor necrosis factor-α (TNF-α) were also measured. Human colon epithelial Caco-2 cells were pre-treated with or without SHMOs and stimulated with TLR4 activator, lipopolysaccharide. Cell viabilities, mitochondrial membrane potential and supernatant matrix metalloprotease 2 (MMP-2) activities were analyzed. Results Increased frequencies of NLRP3 and caspase-1 positive cells were found in the lamina propria of damaged intestinal area of NEC neonates. SHMOs supplementation reduced NEC incidence and pathological damage scores of rats challenged with hypoxia/cold stress. Accumulation of interleukin-1β, interleukin-6 and TNF-α in NEC group were attenuated in SHMOs + NEC group. Protein expression of mTLR4, NLRP3 and caspase-1 were elevated, cytoplasmic IκB-α were reduced, nuclear phospho-NF-κB p65 were increased in the ileum of NEC rats. SHMOs supplementation ameliorated the elevation of mTLR4, NLRP3 and caspase-1, restored IκB-α in the cytoplasmic fraction and reduced phospho-NF-κB p65 in the nuclear fraction in the ileum of NEC rats. SHMOs pre-treatment improved Caco-2 cell viability, mitigated loss of mitochondrial membrane potential and modulated MMP-2 activities in the presence of lipopolysaccharide in-vitro. Conclusions This study provided clinical evidence of involvement of NLRP3 inflammasome in NEC pathology, and demonstrated the protective actions of SHMOs might be owing to the suppression of TLR4/NF-κB/NLRP3-mediated inflammation in NEC." @default.
• W3120133688 created "2021-01-18" @default.
• W3120133688 creator A5020932593 @default.
• W3120133688 creator A5025866715 @default.
• W3120133688 creator A5064676387 @default.
• W3120133688 creator A5084797476 @default.
• W3120133688 date "2021-01-06" @default.
• W3120133688 modified "2023-10-16" @default.
• W3120133688 title "Sialylated human milk oligosaccharides prevent intestinal inflammation by inhibiting toll like receptor 4/NLRP3 inflammasome pathway in necrotizing enterocolitis rats" @default.
• W3120133688 cites W1964986858 @default.
• W3120133688 cites W1965840687 @default.
• W3120133688 cites W1976662817 @default.
• W3120133688 cites W1977475597 @default.
• W3120133688 cites W1982967155 @default.
• W3120133688 cites W1985538633 @default.
• W3120133688 cites W2022003441 @default.
• W3120133688 cites W2023645909 @default.
• W3120133688 cites W2027533251 @default.
• W3120133688 cites W2029263847 @default.
• W3120133688 cites W2069694301 @default.
• W3120133688 cites W2076726741 @default.
• W3120133688 cites W2109601788 @default.
• W3120133688 cites W2110706037 @default.
• W3120133688 cites W2120565867 @default.
• W3120133688 cites W2128956666 @default.
• W3120133688 cites W2134080725 @default.
• W3120133688 cites W2134721504 @default.
• W3120133688 cites W2135630141 @default.
• W3120133688 cites W2149766325 @default.
• W3120133688 cites W2160124838 @default.
• W3120133688 cites W2165275387 @default.
• W3120133688 cites W2167581264 @default.
• W3120133688 cites W2168372496 @default.
• W3120133688 cites W2168448155 @default.
• W3120133688 cites W2169677770 @default.
• W3120133688 cites W2198773258 @default.
• W3120133688 cites W2288139400 @default.
• W3120133688 cites W2323231324 @default.
• W3120133688 cites W2403497407 @default.
• W3120133688 cites W2553487822 @default.
• W3120133688 cites W2602997428 @default.
• W3120133688 cites W2616398309 @default.
• W3120133688 cites W2773711867 @default.
• W3120133688 cites W2809958722 @default.
• W3120133688 cites W2906420888 @default.
• W3120133688 cites W2909059466 @default.
• W3120133688 cites W2912605826 @default.
• W3120133688 cites W4235469056 @default.
• W3120133688 doi "https://doi.org/10.1186/s12986-020-00534-z" @default.
• W3120133688 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7789326" @default.
• W3120133688 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33407596" @default.
• W3120133688 hasPublicationYear "2021" @default.
• W3120133688 type Work @default.
• W3120133688 sameAs 3120133688 @default.
• W3120133688 citedByCount "18" @default.
• W3120133688 countsByYear W31201336882021 @default.
• W3120133688 countsByYear W31201336882022 @default.
• W3120133688 countsByYear W31201336882023 @default.
• W3120133688 crossrefType "journal-article" @default.
• W3120133688 hasAuthorship W3120133688A5020932593 @default.
• W3120133688 hasAuthorship W3120133688A5025866715 @default.
• W3120133688 hasAuthorship W3120133688A5064676387 @default.
• W3120133688 hasAuthorship W3120133688A5084797476 @default.
• W3120133688 hasBestOaLocation W31201336881 @default.
• W3120133688 hasConcept C126322002 @default.
• W3120133688 hasConcept C142724271 @default.
• W3120133688 hasConcept C164027704 @default.
• W3120133688 hasConcept C170493617 @default.
• W3120133688 hasConcept C17991360 @default.
• W3120133688 hasConcept C203014093 @default.
• W3120133688 hasConcept C2776070231 @default.
• W3120133688 hasConcept C2776914184 @default.
• W3120133688 hasConcept C2777209026 @default.
• W3120133688 hasConcept C2777226302 @default.
• W3120133688 hasConcept C2778690821 @default.
• W3120133688 hasConcept C2779303187 @default.
• W3120133688 hasConcept C71924100 @default.
• W3120133688 hasConcept C74172505 @default.
• W3120133688 hasConceptScore W3120133688C126322002 @default.
• W3120133688 hasConceptScore W3120133688C142724271 @default.
• W3120133688 hasConceptScore W3120133688C164027704 @default.
• W3120133688 hasConceptScore W3120133688C170493617 @default.
• W3120133688 hasConceptScore W3120133688C17991360 @default.
• W3120133688 hasConceptScore W3120133688C203014093 @default.
• W3120133688 hasConceptScore W3120133688C2776070231 @default.
• W3120133688 hasConceptScore W3120133688C2776914184 @default.
• W3120133688 hasConceptScore W3120133688C2777209026 @default.
• W3120133688 hasConceptScore W3120133688C2777226302 @default.
• W3120133688 hasConceptScore W3120133688C2778690821 @default.
• W3120133688 hasConceptScore W3120133688C2779303187 @default.
• W3120133688 hasConceptScore W3120133688C71924100 @default.
• W3120133688 hasConceptScore W3120133688C74172505 @default.
• W3120133688 hasFunder F4320321001 @default.
• W3120133688 hasFunder F4320335769 @default.
• W3120133688 hasIssue "1" @default.
• W3120133688 hasLocation W31201336881 @default.
• W3120133688 hasLocation W31201336882 @default.
• W3120133688 hasLocation W31201336883 @default.
• W3120133688 hasLocation W31201336884 @default.
• W3120133688 hasLocation W31201336885 @default.

• next